Xeglyze
(Abametapir Lotion 0.74% w/w)Phase 3Small molecule
Xeglyze is one of 5 small molecule programs targeting Lice Infestation. It is currently in Phase 3.
1
Indications
5
Total Trials
0
Active Trials
4
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Lice Infestation
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Natroba
DDeciphera Pharmaceuticals, LLC
Approved
Xeglyze
LLnhc
Phase 3
Ha44
DDr. Reddy's Laboratories Limited
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lice Infestation3 trials
A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Completed·—·Phase 3·NCT02060903·379 enrolled
Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Completed·—·Phase 3·NCT02062060·325 enrolled
Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation
Completed·—·Phase 2·NCT02097485·50 enrolled
TIA1 trial
Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion
Completed·—·Phase 1·NCT02062073·238 enrolled
Irritation1 trial
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
Completed·—·Phase 1·NCT02061813·40 enrolled
Regulatory
FDA Approval Timeline[4]
Jul 24, 2020
XEGLYZE
NDA NDA206966
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Abametapir Lotion 0.74% w/w. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]